DEGARELIX
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.2M | 371 | 0 |
| 2019 | $1.3M | 424 | 1 |
| 2018 | $843,788 | 207 | 4 |
| 2017 | $143,470 | 121 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.4M | 1,042 | 98.9% |
| Consulting Fee | $27,863 | 5 | 0.8% |
| Travel and Lodging | $8,480 | 31 | 0.2% |
| Food and Beverage | $2,259 | 45 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) | Ferring Pharmaceuticals AS | $1.2M | 0 |
| A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix Gonadotropin-Releasing Hormone GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist | Ferring International Pharmascience Center US | $1.1M | 0 |
| A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix Gonadotropin-Releasing Hormone GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist | Ferring Pharmaceuticals AS | $1.1M | 0 |
| A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix GnRH antagonist or Leuprolide LHRH agonist | Ferring International Pharmascience Center US | $4,725 | 0 |
Top Doctors Receiving Payments for DEGARELIX
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Springfield, IL | $3.4M | 1,042 |
| , MD | Radiation Oncology | Boston, MA | $9,022 | 6 |
| , MD | Internal Medicine | New York, NY | $8,719 | 6 |
| , MD | Hematology & Oncology | Seattle, WA | $6,705 | 10 |
| , M.D | Urology | Durham, NC | $6,361 | 9 |
| , M.D | Cardiovascular Disease | Durham, NC | $3,504 | 20 |
| William Clark | Urology | Anchorage, AK | $1,632 | 7 |
| , MD | Specialist | Tucson, AZ | $1,155 | 11 |
| , M.D | General Practice | Miami, FL | $1,004 | 7 |
| , M.D | Therapeutic Radiology | San Francisco, CA | $262.50 | 1 |
| , MD | Urology | Philadelphia, PA | $237.00 | 4 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 10
- Transactions 1,123
About DEGARELIX
DEGARELIX is a drug associated with $3.5M in payments to 10 healthcare providers, recorded across 1,123 transactions in the CMS Open Payments database. The primary manufacturer is Ferring Pharmaceuticals AS.
Payment data is available from 2017 to 2020. In 2020, $1.2M was paid across 371 transactions to 0 doctors.
The most common payment nature for DEGARELIX is "Unspecified" ($3.4M, 98.9% of total).
DEGARELIX is associated with 4 research studies, including "A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)" ($1.2M).